CDA | Evidence Driven
CDA | Evidence Driven

fecal microbiota

Details

Generic Name:
fecal microbiota
Project Status:
Pending
Therapeutic Area:
Clostridioides difficile infection, prevention
Manufacturer:
Ferring Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0850-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​Indicated to prevent recurrence of Clostridioides difficile infection (CDI) in adults following antibiotic treatment for recurrent CDI.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Indicated to prevent recurrence of Clostridioides difficile infection (CDI) in adults following antibiotic treatment for recurrent CDI.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : November 15, 2024